When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – Adult survivors of childhood cancer, particularly those in poor physical health, are at increased risk for suicidal thoughts, according to an October 19…
NEW YORK (Reuters Health) – Neoadjuvant treatment with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor, can help downstage bladder cancer to organ-confined disease, thereby increasing the…
NEW YORK (Reuters Health) – Treatment with the third generation bisphosphonate zoledronic acid (Zometa) may improve survival in lung cancer patients with bone metastases, Greek researchers report. Between…
NEW YORK (Reuters Health) – While minimally invasive radical prostatectomy (MIRP) offers certain advantages over open retropubic radical prostatectomy (RRP), such as a shorter hospital stay, it also…
NEW YORK (Reuters Health) – Tamoxifen therapy has been linked to an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) and now new research suggests…
NEW YORK (Reuters Health) – In patients receiving first-line treatment for metastatic colon cancer, planned complete discontinuation of chemotherapy had a negative impact on duration of disease control…
NEW YORK (Reuters Health) – In a phase III trial in women with HER2/hormone receptor-copositive metastatic breast cancer, the combination of trastuzumab plus anastrozole improved outcomes compared to…
NEW YORK (Reuters Health) – For patients with primary cutaneous melanoma, targeted high-resolution ultrasound should not be used as a substitute for excisional sentinal lymph node biopsy, new…
NEW YORK (Reuters Health) – In detecting prostate cancer, no single prostate specific antigen (PSA) cut-off value achieves the likelihood ratios usually required of a screening test, according…
NEW YORK (Reuters Health) – New research indicates that over half of men who choose watchful waiting as the initial strategy for prostate cancer require no treatment on…
